Cargando…

Hierarchy‐Assembled Dual Probiotics System Ameliorates Cholestatic Drug‐Induced Liver Injury via Gut‐Liver Axis Modulation

Cholestatic drug‐induced liver injury (DILI) induced by drugs or other xenobiotics is a severe and even fatal clinical syndrome. Here, living materials of hierarchy‐assembled dual probiotics system are fabricated by sequentially encapsulating probiotic Lactobacillus delbrueckii subsp. bulgaricus (LD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Qi‐Wen, Li, Qian‐Ru, Cao, Meng‐Wei, Yan, Jian‐Hua, Zhang, Xian‐Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189648/ https://www.ncbi.nlm.nih.gov/pubmed/35434937 http://dx.doi.org/10.1002/advs.202200986

Ejemplares similares

The Gut-Liver Axis in Cholestatic Liver Diseases
por: Blesl, Andreas, et al.
Publicado: (2021)

Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease
por: Rackayová, Veronika, et al.
Publicado: (2021)

Prolonged Administration of Melatonin Ameliorates Liver Phenotypes in Cholestatic Murine Model
por: Ceci, Ludovica, et al.
Publicado: (2022)

Liver Transplantation for Patients with Cholestatic Liver Diseases
por: Schöning, Wenzel, et al.
Publicado: (2015)

Probiotic Bacillus Alleviates Oxidative Stress-Induced Liver Injury by Modulating Gut-Liver Axis in a Rat Model
por: Wu, Yanping, et al.
Publicado: (2022)

Inhibition of CBP/β‐catenin signaling ameliorated fibrosis in cholestatic liver disease
por: Kimura, Masamichi, et al.
Publicado: (2022)

Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis
por: Gui, Wenfang, et al.
Publicado: (2023)

Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease
por: Shi, Qingmiao, et al.
Publicado: (2023)

Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver
por: Ko, Masayoshi, et al.
Publicado: (2021)

Correction: Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver
por: Ko, Masayoshi, et al.
Publicado: (2023)

Butyrate-Producing Probiotics Reduce Nonalcoholic Fatty Liver Disease Progression in Rats: New Insight into the Probiotics for the Gut-Liver Axis
por: Endo, Hitoshi, et al.
Publicado: (2013)

Fibrosis in Autoimmune and Cholestatic Liver Disease
por: Penz-Österreicher, Melitta, et al.
Publicado: (2011)

Update on pharmacotherapies for cholestatic liver disease
por: Ali, Ahmad H., et al.
Publicado: (2016)

Review: Pathogenesis of cholestatic liver diseases
por: Yokoda, Raquel T, et al.
Publicado: (2020)

The Role of Inflammation in Cholestatic Liver Injury
por: Chen, Jie, et al.
Publicado: (2023)

TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis
por: Liu, Sujie, et al.
Publicado: (2022)

The Role of Liver Biopsy in Investigation of Cholestatic Liver Disease in Infancy
por: Chaudhry, Zoya, et al.
Publicado: (2019)

Folic acid ameliorates alcohol-induced liver injury via gut–liver axis homeostasis
por: Zhang, Huaqi, et al.
Publicado: (2022)

Chronic Cholestatic Liver Injury Attributable to Vedolizumab
por: Stine, Jonathan G., et al.
Publicado: (2016)

Cellular crosstalk during cholestatic liver injury
por: Thomson, Joanne, et al.
Publicado: (2017)

Cholestatic liver diseases: An era of emerging therapies
por: Samant, Hrishikesh, et al.
Publicado: (2019)

The Role of Vitamin K in Cholestatic Liver Disease
por: Sultana, Halima, et al.
Publicado: (2021)

The role of bile acids in cholestatic liver injury
por: Cai, Shi-Ying, et al.
Publicado: (2021)

Fibrotic Events in the Progression of Cholestatic Liver Disease
por: Wu, Hanghang, et al.
Publicado: (2021)

Guidelines for the Management of Cholestatic Liver Diseases (2021)
por: Lu, Lungen
Publicado: (2022)

Human Hepatocellular response in Cholestatic Liver Diseases
por: Ortiz, Kimberly, et al.
Publicado: (2023)

Evaluation and Management of Chronic Cholestatic Liver Diseases
por: Rini, Sandra Surya, et al.
Publicado: (2023)

The HVEM-BTLA Immune Checkpoint Restrains Murine Chronic Cholestatic Liver Injury by Regulating the Gut Microbiota
por: Kou, Yanbo, et al.
Publicado: (2022)

JNKs protect from cholestatic liver disease progression by modulating Apelin signalling
por: Mohamed, Mohamed Ramadan, et al.
Publicado: (2023)

Herbal formula LLKL ameliorates hyperglycaemia, modulates the gut microbiota and regulates the gut‐liver axis in Zucker diabetic fatty rats
por: Li, Mei, et al.
Publicado: (2020)

The role of probiotics and prebiotics in modulating of the gut-brain axis
por: Ansari, Fereshteh, et al.
Publicado: (2023)

Conditional depletion of macrophages ameliorates cholestatic liver injury and fibrosis via lncRNA-H19
por: Tian, Xinbei, et al.
Publicado: (2021)

Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature
por: Milosevic, Ivana, et al.
Publicado: (2019)

Gut Microbiota: Target for Modulation of Gut-Liver-Adipose Tissue Axis in Ethanol-Induced Liver Disease
por: Patel, Dhara, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Properties of Rosmarinic Acid in Rat Cholestatic Liver Injury
por: Min, Jianbin, et al.
Publicado: (2018)

Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease
por: Xu, Yu, et al.
Publicado: (2021)

Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
por: Halilbasic, Emina, et al.
Publicado: (2013)

Recent developments in the management of idiopathic cholestatic liver disease
por: Imam, Mohamad H., et al.
Publicado: (2012)

Bile Nephropathy in Flucloxacillin-Induced Cholestatic Liver Dysfunction
por: Alnasrallah, Basil, et al.
Publicado: (2016)

Current and future therapies for inherited cholestatic liver diseases
por: van der Woerd, Wendy L, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o70gmohuqle3euf2gd09ct6b5o